<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00730223</url>
  </required_header>
  <id_info>
    <org_study_id>040062</org_study_id>
    <secondary_id>GM31304</secondary_id>
    <secondary_id>CFAR Discovery Grant</secondary_id>
    <nct_id>NCT00730223</nct_id>
  </id_info>
  <brief_title>Genetic Determinants of the Metabolism of Non-nucleoside Reverse Transcriptase Inhibitors</brief_title>
  <official_title>Genetic Determinants of the Metabolism of Non-nucleoside Reverse Transcriptase Inhibitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To see if certain variations in the CYP2B6 gene contribute to differences in plasma drug
      levels and central nervous system side affects in people who take nevirapine or efavirenz.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">March 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of single dose nevirapine and single dose efavirenz</measure>
    <time_frame>5-6 weeks</time_frame>
  </primary_outcome>
  <enrollment type="Actual">33</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nevirapine and Efavirenz</intervention_name>
    <description>single oral dose 200mg of nevirapine and single oral dose 600 mg of efavirenz</description>
    <other_name>Viramune</other_name>
    <other_name>Sustiva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy African American men and women.

          -  18-55 years of age.

          -  Willing and able to provide written informed consent.

        Exclusion Criteria:

          -  Currently or recently (within the previous 30 days) received medications known or
             likely to be metabolized by, or interact wth the CYP450 enzymes.

          -  Prior or current hepatic or psychiatric disease illness that in the judgment of the
             investigator would interfere in the study performance.

          -  Active alcohol or illicit drug abuse use that in the judgment of the investigator
             would interfere in the study performance.

          -  Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) &gt;1.5 X upper limit
             of normal.

          -  Positive pregnancy test in women of childbearing potential.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David W Haas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Professor of Medicine</affiliation>
  </overall_official>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2008</study_first_submitted>
  <study_first_submitted_qc>August 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2008</study_first_posted>
  <last_update_submitted>February 12, 2013</last_update_submitted>
  <last_update_submitted_qc>February 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>David Haas</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Nevirapine</keyword>
  <keyword>Efavirenz</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>healthy</keyword>
  <keyword>CYP2B6</keyword>
  <keyword>HIV/AIDS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Nevirapine</mesh_term>
    <mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

